Alzinova AB (publ) (STO:ALZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.583
-0.008 (-1.35%)
At close: Mar 6, 2026
-79.33%
Market Cap 60.82M
Revenue (ttm) 26.12M
Net Income (ttm) -26.94M
Shares Out 104.32M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 141,996
Average Volume 428,936
Open 0.610
Previous Close 0.591
Day's Range 0.583 - 0.617
52-Week Range 0.570 - 3.820
Beta 1.30
RSI 25.26
Earnings Date Feb 26, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s d... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol ALZ
Full Company Profile

Financial Performance

In 2024, Alzinova AB's revenue was 16.81 million, a decrease of -15.41% compared to the previous year's 19.87 million. Losses were -20.55 million, 24.7% more than in 2023.

Financial Statements

News

There is no news available yet.